FGen
FGen combines biological engineering and high throughput screening for the design of microbial strains that enable the efficient and cost-competitive bioproduction of chemicals and proteins.
| EUR | 2015 | 2016 | 2017 | 2018 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 1 % | (8 %) | 4 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
FGen is a pioneering startup in the field of synthetic biology and industrial biotechnology. The company specializes in the design and optimization of microbial strains, which are essentially engineered microorganisms used to produce chemicals and proteins in a more efficient and cost-effective manner. This process is achieved through a combination of biological engineering and high throughput screening—a method that allows for the rapid testing of thousands of microbial strains to identify the most productive ones.
FGen primarily serves clients in various industrial sectors, including chemicals, food, feed ingredients, and pharmaceuticals. The company collaborates with multinational corporations and leading global producers to enhance their production strains, making the bioproduction process more efficient and sustainable. For instance, FGen has recently partnered with a global feed ingredient producer to optimize their current production strain, and with a multinational company in the food sector to improve fungal protein production strains.
The market FGen operates in is known as white biotechnology, which focuses on the use of biological processes for industrial purposes. This market is growing rapidly due to the increasing demand for sustainable and eco-friendly production methods.
FGen's business model revolves around partnerships and collaborations. The company works closely with its clients to tailor microbial strains to their specific production needs. Revenue is generated through these collaborative projects, which often involve long-term contracts and milestone-based payments. Additionally, FGen may receive royalties based on the commercial success of the optimized strains.
In summary, FGen is at the forefront of industrial biotechnology, leveraging advanced biological engineering and high throughput screening to revolutionize the production of chemicals and proteins. The company's innovative approach not only enhances efficiency but also promotes sustainability in various industrial sectors.
Keywords: Synthetic biology, industrial biotechnology, microbial strains, high throughput screening, biological engineering, chemicals, proteins, collaboration, optimization, sustainability.